Nie nadaje si do spoycia ani stosowania przez ludzi i zwierzta domowe
52 In a phase 1b trial done to evaluate the safety, pharmacokinetics and pharmacodynamics of orforglipron in patients with T2DM, orforglipron resulted in significant reductions in HbA1c, fasting blood glucose and body weight, with an adverse event profile consistent with that of other GLP-1RA
1 Introduction Since its introduction in 1921, insulin has changed the management and prognosis of patients with type 1 diabetes (T1D)
Alcuni dei nostri clienti Nomos una Software House indipendente, di pluriennale esperienza, da sempre innovativa ed orientata alle esigenze del Cliente La nostra MISSIONE progettare soluzioni software su misura, aderenti ai requisiti della Clientela, che siano robuste, scalabili ed evolvibili
Cedarbaum JM, et al
Utilization Management : Designing efficient prior authorization and care management processes tailored to GLP-1 medications